Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.83 |
| ▸ | CHEK2 | O96017 | 13/20 | 0.81 |
| ▸ | MMP2 | P08253 | 1/20 | 0.78 |
| ▸ | MMP9 | P14780 | 1/20 | 0.78 |
| ▸ | MMP8 | P22894 | 1/20 | 0.78 |
| ▸ | MMP13 | P45452 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | MPL | P40238 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20982644 | 0.98 | NR4A2 (0.86) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL20982511 | 0.94 | MMP2 (0.78) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL20982594 | 0.92 | NR4A2 (0.77) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL27652687 | 0.92 | NR4A2 (0.77) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL3178116 | 0.92 | CHEK2 (0.78) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL3178995 | 0.91 | CHEK2 (0.97) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL2339157 | 0.91 | MMP2 (0.84) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL29576909 | 0.91 | NR4A2 (0.75) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL30938560 | 0.91 | NR4A2 (1.00) | NR4A2CHEK2MMP2MMP9MMP8 | |
| SCHEMBL28384472 | 0.91 | NR4A2 (0.75) | NR4A2CHEK2MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | LABORDE EDGARDO (US) | 2001-09-27 | — | — | US | claimed |
| US-6251689-B1 | BINDING TO RESIN; OXIDATION | TELIK, INC. | 2001-06-26 | — | — | US | claimed |
| EP-3611224-A1 | COMPOSITION, COMPOSITE FILM AND MEMBRANE ELECTRODE ASSEMBLY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-7282518-B2 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | SIRCAR JAGADISH C | 2007-08-30 | — | — | US | disclosed |
| EP-1368028-B1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | SIRCAR JAGADISH C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6759425-B2 | USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. | AVANIR PHARMACEUTICALS | 2004-07-06 | — | — | US | disclosed |
| CN-1496257-A | Benzimidazole compounds for modulating immunoglobulin E and inhibiting cell proliferation | ������˹ҩƷ��˾ | 2004-05-12 | — | — | CN | disclosed |
| EP-1368028-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072090-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2002-09-19 | — | — | US | disclosed |
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | LABORDE EDGARDO (US) | 2001-09-27 | — | — | US | disclosed |
| US-6251689-B1 | BINDING TO RESIN; OXIDATION | TELIK, INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | MKI67, CMA1, CCNI | NR4A2 1970/4885CHEK2 2484/4885MMP2 760/4885 |
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | EIF2AK2, CDK15, CDK17 | NR4A2 3541/4885CHEK2 152/4885MMP2 1131/4885 |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | FCER2, CMA1, FCGR1A | NR4A2 2543/4885CHEK2 3296/4885MMP2 532/4885 |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | MKI67, CMA1, CCNI | NR4A2 1970/4885CHEK2 2484/4885MMP2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.